India, Nov. 6 -- Healthcare stocks moved higher following clinical, financial and corporate updates. Developments included positive melanoma therapy data, a reverse stock split, stronger quarterly revenue, planned acquisition financing and preclinical immunotherapy findings.
Read on.....
Obsidian Therapeutics, Inc. (OBX)
Shares surged 38.33% after Obsidian reported a 67% objective response rate for its investigational TIL therapy amsoki-cel in advanced melanoma. Five responses remained ongoing at a median follow-up of 14.3 months. Median progression-free survival was 8.3 months, while pooled safety data from 37 patients showed no dose-limiting toxicities, treatment-related deaths, ICANS or ICU transfers. Topline Agni-01 data are expected...